Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/62227
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Effect of maraviroc on HIV disease progression-related biomarkers |
Autor: | Romero-Sánchez, M.; Machmach, K.; González-Serna, Manuel Alejandro; Genebat, Miguel CSIC; Pulido, Ildefonso CSIC ORCID; García-García, María; Álvarez-Ríos, Ana Isabel CSIC ORCID; Ferrando-Martínez, Sara; Ruiz-Mateos, Ezequiel CSIC ORCID; Leal, Manuel CSIC | Fecha de publicación: | 2012 | Editor: | American Society for Microbiology | Citación: | Antimicrobial Agents and Chemotherapy 56(11): 5858-5864 (2012) | Resumen: | The potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test (MCT) can be used in selecting patients to receive MVC-containing combined antiretroviral therapy (cART). Using this MCT model, we assessed the effect of MVC on several HIV disease progression biomarkers during the MCT (MVC-specific effect) and following short-term (12-week) cART. We compared 45 patients on MVC monotherapy with a control group of 25 patients on MVC-sparing cART. We found that MVC did not modify any biomarkers in patients that had no virological response after the MCT. MVC-specific effects in patients with virological responses included increased CD8 + T-cell activation and senescence levels, preservation of an increase in soluble CD14 (sCD14), and a decrease in D dimer levels. After 12 weeks, MVC-containing cART increased CD8 + T-cell counts and preserved CD4 + T-cell senescence levels compared with MVC-sparing cART. Moreover, there was a decrease in sCD14 levels in patients that received MVC-containing cART. In conclusion, effects compatible with CD8 + T-cell redistribution in peripheral blood were observed after MVC therapy. However, MVC was associated with a favorable profile in HIV disease progression biomarkers only in patients with a virological response. These results support a potential clinical benefit of a therapy which includes MVC in HIV-infected patients. Copyright © 2012, American Society for Microbiology. All Rights Reserved. | URI: | http://hdl.handle.net/10261/62227 | DOI: | 10.1128/AAC.01406-12 | Identificadores: | doi: 10.1128/AAC.01406-12 issn: 0066-4804 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
7
checked on 19-mar-2024
SCOPUSTM
Citations
17
checked on 21-mar-2024
WEB OF SCIENCETM
Citations
17
checked on 23-feb-2024
Page view(s)
326
checked on 29-mar-2024
Download(s)
108
checked on 29-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.